Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00160654|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 15, 2013
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.
The optimal dose in daily clinical practice will be used.
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy, Partial||Drug: Levetiracetam||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||345 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||May 2006|
|Actual Study Completion Date :||May 2006|
- To assess safety of levetiracetam
- To evaluate efficacy of levetiracetam in community based practice.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160654
|Hong Kong, Hong Kong|
|Kwun Tong (Kowloon), Hong Kong|
|Kuala Llumpur, Malaysia|
|Kaohsiung County, Taiwan|
|Taoyuan County, Taiwan|
|Khon Kaen, Thailand|
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|